JPWO2020166592A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020166592A5 JPWO2020166592A5 JP2020572264A JP2020572264A JPWO2020166592A5 JP WO2020166592 A5 JPWO2020166592 A5 JP WO2020166592A5 JP 2020572264 A JP2020572264 A JP 2020572264A JP 2020572264 A JP2020572264 A JP 2020572264A JP WO2020166592 A5 JPWO2020166592 A5 JP WO2020166592A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- anticancer
- formula
- antibody
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001093 anti-cancer Effects 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 239000000611 antibody drug conjugate Substances 0.000 claims 7
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229940043355 kinase inhibitor Drugs 0.000 claims 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000008512 biological response Effects 0.000 claims 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229950005646 imgatuzumab Drugs 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 230000004481 post-translational protein modification Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229960004539 alirocumab Drugs 0.000 claims 1
- 229950001537 amatuximab Drugs 0.000 claims 1
- 229950005794 anrukinzumab Drugs 0.000 claims 1
- 229950003145 apolizumab Drugs 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950005122 atinumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 229940075127 azintuxizumab Drugs 0.000 claims 1
- 229960004669 basiliximab Drugs 0.000 claims 1
- 229950007843 bavituximab Drugs 0.000 claims 1
- 229960003270 belimumab Drugs 0.000 claims 1
- 229950000321 benralizumab Drugs 0.000 claims 1
- 229950010559 besilesomab Drugs 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229950008086 bezlotoxumab Drugs 0.000 claims 1
- 229950006326 bimagrumab Drugs 0.000 claims 1
- 229950002853 bimekizumab Drugs 0.000 claims 1
- 229950000009 bleselumab Drugs 0.000 claims 1
- 229960003008 blinatumomab Drugs 0.000 claims 1
- 229950011350 bococizumab Drugs 0.000 claims 1
- 229960000455 brentuximab vedotin Drugs 0.000 claims 1
- 229960002874 briakinumab Drugs 0.000 claims 1
- 229960003735 brodalumab Drugs 0.000 claims 1
- 229950000025 brolucizumab Drugs 0.000 claims 1
- 229950009653 camidanlumab Drugs 0.000 claims 1
- 229950009658 cofetuzumab Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229950008962 detumomab Drugs 0.000 claims 1
- 229950006723 dezamizumab Drugs 0.000 claims 1
- 229960004497 dinutuximab Drugs 0.000 claims 1
- 229950003468 dupilumab Drugs 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 229950011453 dusigitumab Drugs 0.000 claims 1
- 229940096918 enapotamab Drugs 0.000 claims 1
- 229950008579 ertumaxomab Drugs 0.000 claims 1
- 229950004912 etrolizumab Drugs 0.000 claims 1
- 229960002027 evolocumab Drugs 0.000 claims 1
- 229950001488 faralimomab Drugs 0.000 claims 1
- 229950009929 farletuzumab Drugs 0.000 claims 1
- 229950010512 fezakinumab Drugs 0.000 claims 1
- 229950008085 figitumumab Drugs 0.000 claims 1
- 229950010043 fletikumab Drugs 0.000 claims 1
- 229950004923 fontolizumab Drugs 0.000 claims 1
- 229950004356 foralumab Drugs 0.000 claims 1
- 229950002140 futuximab Drugs 0.000 claims 1
- 229950000118 galcanezumab Drugs 0.000 claims 1
- 229950001109 galiximab Drugs 0.000 claims 1
- 229950004896 ganitumab Drugs 0.000 claims 1
- 229950002508 gantenerumab Drugs 0.000 claims 1
- 229940057296 gatipotuzumab Drugs 0.000 claims 1
- 229950003717 gevokizumab Drugs 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 229950010864 guselkumab Drugs 0.000 claims 1
- 229950010245 ibalizumab Drugs 0.000 claims 1
- 229960002308 idarucizumab Drugs 0.000 claims 1
- 229950007275 ifabotuzumab Drugs 0.000 claims 1
- 229950002200 igovomab Drugs 0.000 claims 1
- 229950007243 mirvetuximab Drugs 0.000 claims 1
- 229950007708 namilumab Drugs 0.000 claims 1
- 229960005027 natalizumab Drugs 0.000 claims 1
- 229950005790 navicixizumab Drugs 0.000 claims 1
- 229950010591 navivumab Drugs 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229950010012 nemolizumab Drugs 0.000 claims 1
- 229950009675 nerelimomab Drugs 0.000 claims 1
- 229950002697 nesvacumab Drugs 0.000 claims 1
- 229950009007 orticumab Drugs 0.000 claims 1
- 229950005374 ruplizumab Drugs 0.000 claims 1
- 229950000106 samalizumab Drugs 0.000 claims 1
- 229950006348 sarilumab Drugs 0.000 claims 1
- 229940060041 satralizumab Drugs 0.000 claims 1
- 229950007308 satumomab Drugs 0.000 claims 1
- 229960004540 secukinumab Drugs 0.000 claims 1
- 229950008684 sibrotuzumab Drugs 0.000 claims 1
- 229960003323 siltuximab Drugs 0.000 claims 1
- 229950009513 simtuzumab Drugs 0.000 claims 1
- 229950003804 siplizumab Drugs 0.000 claims 1
- 229950007874 solanezumab Drugs 0.000 claims 1
- 229950011267 solitomab Drugs 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229950006757 timolumab Drugs 0.000 claims 1
- 229960003989 tocilizumab Drugs 0.000 claims 1
- 229950008836 tosatoxumab Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229950000835 tralokinumab Drugs 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 229950010086 tregalizumab Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- -1 2,5-dioxopyrrolidin-1-yl Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019023961 | 2019-02-13 | ||
| JP2019023961 | 2019-02-13 | ||
| PCT/JP2020/005291 WO2020166592A1 (ja) | 2019-02-13 | 2020-02-12 | ヘミアスタリン誘導体とその抗体薬物複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020166592A1 JPWO2020166592A1 (ja) | 2021-12-09 |
| JPWO2020166592A5 true JPWO2020166592A5 (https=) | 2022-12-22 |
| JP7479302B2 JP7479302B2 (ja) | 2024-05-08 |
Family
ID=72043950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572264A Active JP7479302B2 (ja) | 2019-02-13 | 2020-02-12 | ヘミアスタリン誘導体とその抗体薬物複合体 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US12178879B2 (https=) |
| JP (1) | JP7479302B2 (https=) |
| WO (1) | WO2020166592A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9508195D0 (en) | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| CA2225325A1 (en) | 1997-12-19 | 1999-06-19 | The University Of British Columbia | Hemiasterlin analogs |
| US20030100088A1 (en) | 2001-07-13 | 2003-05-29 | Sigler Gerald F. | Protease inhibitor conjugates and antibodies useful in immunoassay |
| KR101208266B1 (ko) | 2002-03-22 | 2012-12-05 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 헤미아스텔린 유도체 및 이의 용도 |
| US7064211B2 (en) | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
| WO2004026293A2 (en) | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| WO2014057436A2 (en) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
| EP2927227A4 (en) | 2013-01-03 | 2015-12-30 | Celltrion Inc | ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH |
| HK1220626A1 (zh) | 2013-03-15 | 2017-05-12 | The Centre For Drug Research And Development | 具细胞毒性和抗有丝分裂的化合物以及其使用方法 |
| WO2015095953A1 (en) | 2013-12-27 | 2015-07-02 | The Centre For Drug Research And Development | Sulfonamide-containing linkage systems for drug conjugates |
| BR112016015105A8 (pt) | 2013-12-27 | 2018-04-24 | Var2 Pharmaceuticals Aps | conjugados var2csa-droga |
| GB201402009D0 (en) | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| JP6938154B2 (ja) | 2014-11-07 | 2021-09-22 | 国立大学法人大阪大学 | 未分化細胞が除去された分化誘導細胞集団、その利用及びその製造方法 |
| PT3250237T (pt) | 2015-01-30 | 2021-06-30 | Sutro Biopharma Inc | Derivados de hemiasterlina para conjugação e terapêutica |
| WO2015151079A2 (en) | 2015-06-20 | 2015-10-08 | Hangzhou Dac Biotech Co, Ltd | Auristatin analogues and their conjugates with cell-binding molecules |
| EP4321523A3 (en) | 2017-08-10 | 2024-04-24 | Sumitomo Pharma Co., Ltd. | Hemiasterlin derivatives and antibody-drug conjugates including same |
| PL3666787T3 (pl) * | 2017-08-10 | 2024-04-29 | Sumitomo Pharma Co., Ltd. | Koniugaty przeciwciało-lek zawierające pochodną hemiasterliny |
| JP7437328B2 (ja) * | 2019-02-13 | 2024-02-22 | 住友ファーマ株式会社 | 多能性幹細胞の除去剤 |
-
2020
- 2020-02-12 WO PCT/JP2020/005291 patent/WO2020166592A1/ja not_active Ceased
- 2020-02-12 JP JP2020572264A patent/JP7479302B2/ja active Active
- 2020-02-12 US US17/429,427 patent/US12178879B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020166592A5 (https=) | ||
| JP7623413B2 (ja) | ヘミアスタリン誘導体を含む抗体薬物複合体 | |
| JP7605809B2 (ja) | ヘミアスタリン誘導体及びこれらの抗体薬物複合体 | |
| JP2024532726A5 (https=) | ||
| JP7570641B2 (ja) | 癌の処置又は予防において使用する為のキノリン誘導体 | |
| JP7479302B2 (ja) | ヘミアスタリン誘導体とその抗体薬物複合体 | |
| JP2020132638A5 (https=) | ||
| JPWO2019031614A5 (https=) | ||
| JP7560255B2 (ja) | ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬 | |
| US11725048B2 (en) | CXCL10 binding proteins and compositions thereof | |
| WO2024078449A1 (en) | Compounds, compositions and methods | |
| WO2022216978A1 (en) | Phthalocyanine dye compounds, conjugates and methods of use thereof | |
| JP7432531B2 (ja) | システイン残基を有するヘミアスタリン誘導体 | |
| WO2026037321A1 (en) | Compounds, compositions and methods | |
| CA3238784A1 (en) | Stapled peptide-antibody conjugates (spacs) and uses thereof | |
| OA22197A (en) | Compounds, Compositions And Methods. | |
| TW202517255A (zh) | 化合物、組合物及方法 | |
| HK40065482A (en) | Hemiasterlin derivative having cysteine residue |